PATH vs SGMT
Uipath Inc (PATH) versus Sagimet Biosciences Inc. Series A Common Stock (SGMT) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported SGMT revenue for 2023-09-30 was $2.0M. Net income was -$6.4M. Revenue was up 0.0% from 2023-07-31 to 2023-09-30. SGMT currently screens at market cap $403.2M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. SGMT currently screens at market cap $403.2M.
Not investment advice. Open the PATH and SGMT stock pages for the full models.
Not investment advice.